The Coleman Foundation Comprehensive Lung Cancer Clinic is a multidisciplinary group of highly trained physicians that provides comprehensive care for patients diagnosed with, or suspected to have, lung cancer and other malignancies of the chest. These include:

• Lung cancer
• Mesothelioma
• Chest sarcomas
• Thymomas
• Lung metastases
• Lung nodules
• Lung masses
• Lung infiltrates

The Coleman Foundation Comprehensive Lung Cancer Clinic provides a full range of the latest diagnostic and most innovative treatment options, including minimally invasive surgery (VATS), groundbreaking targeted therapies, advanced chemotherapy approaches, the latest radiation treatments and a full range of surgical options for both early and advanced lung cancer. In a single visit, patients receive a comprehensive assessment and discussion of treatment options provided by our team of experts. 

In most instances, treatment recommendations are made that may include minimally invasive thoracic surgery, chemotherapy, biologic targeted therapies, radiation therapy, or a combination of these therapies. Treatment options also include the opportunity to participate in a wide range of clinical trials. Additionally, we offer complementary and integrative cancer medicine and supportive services for patients and their families. 

For more information, please visit our Lung Cancer Clinic Services page.

The successful treatment of lung cancer requires not only experience, skill and innovative therapeutic treatment options, it requires compassion and understanding. At Rush University Medical Center, a highly skilled team of oncologists, surgeons, radiologists, radiation therapists and pulmonologists meet with each patient and their family to create an individualized treatment plan at your initial appointment. For more information, please visit our Lung Cancer Clinical Team page.

Clinical Trials

Physicians at Rush are constantly striving to uncover better treatments and methods of early detection for lung cancer.  In recent years there have been a number of promising advances, including an approach pioneered at Rush that involves using a combination of radiation therapy and chemotherapy to treat some forms of lung cancer.  Additionally, Rush was one of the institutions to investigate the value of combining Celebrex, an anti-inflammatory drug, with Tarceva or with chemotherapy in treating lung cancer in patients. Our observations suggested that Celebrex might provide benefit for patients whose tumors have high expression of the COX-2 enzyme – a promising lead that is being pursued in current research studies at Rush. 

For more information about our current research and clinical trials, please see our Lung Cancer Clinical Trials page.